Journal article
Zanubrutinib for the treatment of MYD88 wild-type Waldenström macroglobulinemia: A substudy of the phase 3 ASPEN trial
M Dimopoulos, RG Sanz, HP Lee, M Trneny, M Varettoni, S Opat, S D'Sa, RG Owen, G Cull, S Mulligan, J Czyz, JJ Castillo, M Motta, T Siddiqi, MG Mesa, MG Gorrochategui, D Talaulikar, PL Zinzani, E Askari, S Grosicki Show all
Blood Advances | ELSEVIER | Published : 2020
Abstract
Patients with Waldenström macroglobulinemia (WM) lacking activating mutations in the MYD88 gene (MYD88WT) have demonstrated relatively poor outcomes to ibrutinib monotherapy, with no major responses reported in a phase 2 pivotal study. Zanubrutinib is a novel, selective Bruton tyrosine kinase (BTK) inhibitor designed to maximize BTK occupancy and minimize off-target activity. The ASPEN study consisted of a randomized comparison of zanubrutinib and ibrutinib efficacy and safety in patients with WM who have the MYD88 mutation, as well as a separate cohort of patients without MYD88 mutation (MYD88WT) or with unknown mutational status who received zanubrutinib. Results from the latter single-arm..
View full abstractGrants
Funding Acknowledgements
This study was supported by research funding from BeiGene Inc., US; and medical writing and editorial assistance were funded by BeiGene and provided by Gordon Bray and Bio Connections, LLC.